Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(21 sites) United States
Yale University, New Haven, Connecticut Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia University of Chicago Comprehensive Cancer Center, Chicago, Illinois UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois University of Chicago Medicine-Orland Park, Orland Park, Illinois UChicago Medicine Northwest Indiana, Crown Point, Indiana University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland Dana-Farber Cancer Institute, Boston, Massachusetts Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters, Missouri Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri Washington University School of Medicine, St Louis, Missouri Siteman Cancer Center-South County, St Louis, Missouri Siteman Cancer Center at Christian Hospital, St Louis, Missouri Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey Memorial Sloan Kettering Monmouth, Middletown, New Jersey Memorial Sloan Kettering Bergen, Montvale, New Jersey Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey Memorial Sloan Kettering Commack, Commack, New York Memorial Sloan Kettering Westchester, Harrison, New York Memorial Sloan Kettering Cancer Center, New York, New York Memorial Sloan Kettering Nassau, Uniondale, New York